



Relationship between Serum Aminotransferase Levels and Metabolic Disorders in Northern China

*H Zhang¹, Yh Ding², Qm Li³, J Sun¹, Sm He¹, Xw Feng¹, Yl Zhao⁴, Xj Zhou⁵, Yj Cai¹, C Wang¹, Xd Shi¹, Zf Wang¹, Q Zhou¹, *Jq Niu¹*

¹*Dept. of Hepatology, First Hospital, Jilin University, Changchun 130021, China*

²*Phase One Clinical Trial Unit, First Hospital, Jilin University, Changchun 130021, China*

³*Dept. of Pediatric Nephrology, First Hospital, Jilin University, Changchun 130021, China*

⁴*Dept. of Nephrology, the Second Part of First Hospital, Jilin University, Changchun 130021, China*

⁵*Dept. of Rheumatology, First Hospital, Jilin University, Changchun 130021, China*

(Received 28 May 2011; accepted 12 Dec 2011)

Abstract

Background: Increasing evidence suggests an association between elevated serum aminotransferase levels and metabolic disorders (metabolic syndrome, hyperlipemia and diabetes mellitus). However, the significance of relatively low levels of aminotransferases in relation to metabolic disorders has not been fully investigated in the general population. We investigated the association between serum aminotransferase levels and metabolic disorders using data from a survey in Jilin province, China.

Methods: In 2007, a survey was conducted throughout Jilin, China, covering both urban and rural areas. A total of 3835 people, 18 to 79 years old including 1761 men and 2074 women, underwent real-time ultrasonography, blood tests including aspartate aminotransferase and alanine aminotransferase, and had interviews with a structured questionnaire.

Results: Serum aminotransferase levels within the normal range were associated with metabolic syndrome independent of age, occupation, cultural and educational level, income, body mass index, waist circumference, smoking, and alcohol intake. Compared with the lowest level (<20 IU/L), the adjusted odds ratios for ALT levels of 20-29, 30-39, 40-49 and >50 IU/L were 1.92, 2.50, 2.97, and 3.52 in men, and 1.38, 1.54, 3.06, and 2.62 in women, respectively. Near-normal serum aminotransferase levels associated with hyperlipemia, NAFLD, DM were also found in the study.

Conclusions: Normal to near-normal serum aminotransferase levels are associated with metabolic disorders. Serum ALT levels of 21-25 IU/L for men, and 17-22 IU/L for women are suggested as cutoff levels that detect metabolic disorders affecting the liver.

Keywords: Alanine aminotransferase, Metabolic syndrome, Non-alcoholic fatty liver disease, Ultrasonography, Cutoff Levels

Introduction

Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized condition whose prevalence parallels the recent increase in obesity (1-3). NAFLD has also been associated with metabolic disorders, including central obesity, dyslipidemia, hypertension, and hyperglycemia (4-8). In addition, metabolic syndrome (MS), obesity, and insulin resistance are major risk factors in the pathogenesis of NAFLD (9-12). The co-existence of multiple metabolic disorders

is associated with a potentially progressive, severe liver disease. The increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately metabolic syndrome puts a very large population at risk of liver failure (13). Patients with metabolic disorders usually have elevated serum aminotransferase activity, and so aminotransferase assays are widely used to monitor liver function in people with metabolic disorders (14). However, many

liver diseases are not detected by the currently defined range of normal serum aminotransferase levels (15-16). The significance of serum aminotransferase levels, including those that are in the normal and near-normal range, needs to be reviewed in relation to the metabolic disorders. Three hundred and eighteen non-diabetic patients with NAFLDs were investigated for changes in liver enzymes, and to analyze the association between liver enzymes and metabolic syndrome in Shanghai, China (16). However, few large studies have been made in the adult population in China.

Accordingly, we investigated the independent association between serum aminotransferase levels and metabolic disorders in a representative population in northern China. Individuals with MS, hyperlipidemia or diabetes mellitus (DM) were defined as having metabolic disorders in the present study.

Materials and Methods

Design and study population

A prospective survey study of aminotransferase levels and the metabolic disorders was carried out in Dehui, Jilin, China in 2007 (population approximately 800,000). Dehui is located 81 km from Changchun, the largest city in the area. The earnings of most inhabitants of Dehui are in the middle of the income range. The sex and age distribution of inhabitants are similar to those of the province in general. Therefore, Dehui City is representative of other areas in the province in terms of the level of life, economic and cultural development.

A two-stage, tiered-system sampling method was used. This survey was comprehensive and included geographic, economic, cultural, and other parameters. There are 308 villages and 51 neighborhood committees in Dehui. The first survey covered rural areas, and the second covered urban areas. Each stage was divided into two layers. In the first layer, the populations of the villages or neighborhood committees were sorted, and the villages or neighborhood committees were selected by a computer accord-

ing to the principle of equidistant random samples of the population size. We selected 9 villages and 11 neighborhood committees. In the second layer, the households were marked by the distance from the center of the villages or neighborhood committees, and they were selected according to the principle of equidistant random samples of the distance. Then, 150-200 or 80-100 households were computer-selected in villages or neighborhood committees, respectively. A sample of the general population in the selected households consisting of individuals who were at least 18 years of age, and had lived in the same area for more than 10 years was selected using a systematic random 1-in-3 sampling procedure from the census list, which had been updated on February 1, 2007.

We defined sample sizes of urban and rural groups according to the formula of estimation of sample size: $N=(t/d)^2 * (1-P) / P$ ($t=1.96$, $P=0.114$ and $d=0.1$) (4). They were 1800 and 2700 based on the ratio of urban and rural populations of the area, and the total was 4500 (more than the value of N).

In the end, 4298 people responded and agreed to participate in the study, and their serum samples, demographic information, and behavioral factors were collected.

The response rate was high (95.51%, 4298/4500). When we analyzed the relationship between aminotransferase levels and the metabolic disorders, we excluded 75 people who had abnormal autoantibodies, ceruloplasmin, and iron tests. They consisted of 30, 29, 16 people, respectively. In addition, 151 people who reported consuming at least 40 g of alcohol per day were excluded. We also excluded 45 HCV-positive people and 192 HBV-positive people. In the end, 3835 people (1761 men and 2074 women) were eligible for our analyses.

Data collection and blood sampling

The selected participants were asked to fast overnight (≥ 8 h) and attend a local health center for their scheduled appointments. The selected subjects were visited at home if they could not attend the local health center. An interview us-

ing the structured questionnaire was conducted at the time of the participant's visit. The questionnaire included the following questions: 1) How long have you been smoking? 2) Do you drink alcohol (the number and type of drinks per day)? 3) What is your occupation (peasant, laborer, small private businessman or cadre official)? 4) How many years did you study? 5) How much is your income every month? 6) What is your date of birth, sex, and place of residence? Information on demographics (date of birth, sex, place of residence, ethnicity, family size) and behavioral factors (drinking, smoking, occupation, education level, income) was obtained. The study protocol was approved by the Institutional Review Board of the First Hospital of Jilin University. After written informed consent was obtained, blood samples were taken from each participant for seroprevalence analyses. Sera were stored at -20°C until tested at the First Hospital of Jilin University. Anthropometric measurements including height, weight, and waist and hip circumference were conducted by well-trained examiners on individuals wearing light clothing. Waist circumference was measured to the nearest 0.1 cm at the midpoint between the lower borders of the rib cage and the iliac crest. Abdominal ultrasonography was performed to detect the presence of fatty infiltration in the liver by physicians specializing in diagnostic imaging, all of whom used standard criteria in evaluating the images for hepatic fat (17). Fatty liver was diagnosed by concurrence of 3 ultrasonographers, who were unaware of the subjects' clinical and biochemical status. The results were supplemented by the liver-spleen density gradient (LSDG) determined with the non-contrast abdominal computer tomography (CT) in the local hospital.

Serological testing

HBsAg, anti-HCV, glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride and liver enzymes, including ALT, and AST were evaluated by standard methods using kits from Ke Hua (Shanghai, China). ANA, ceruloplasmin and iron studies were also assayed by

standard methods with kits from Ke Hua (Shanghai, China). All laboratory analyses were performed at the First Hospital of Jilin University.

Definition of the metabolic syndrome, hyperlipidemia, NAFLD, DM

The diagnosis of metabolic syndrome was based on the new International Diabetes Federation definition (18), in which central obesity is an essential parameter ($\text{BMI} \geq 25$). We used a modified waist circumference cutoff of ≥ 90 cm in men and ≥ 80 cm in women. Metabolic syndrome was then defined in any individuals who had two or more of the four following criteria: 1) high blood pressure ($\geq 130/85$ mmHg) or undergoing treatment for high blood pressure with anti-hypertensive medication, 2) elevated fasting blood glucose (≥ 5.6 mmol/L) or treatment with anti-diabetic medication, 3) hypertriglyceridemia (≥ 1.7 mmol/L), and 4) low HDL-cholesterol (men, < 1.03 mmol/L; women, < 1.29 mmol/L).

Individuals having one or more of the four following criteria were defined as having hyperlipidemia: 1) hypertriglyceridemia (> 1.7 mmol/L), 2) HDL-cholesterol (men, < 1.04 mmol/L; women, < 1.3 mmol/L), 3) LDL-cholesterol (> 4.3 mmol/L), 4) total cholesterol (> 6.0 mmol/L).

Individuals having the following criteria were defined as having NAFLD: 1) consuming < 40 g alcohol per week, 2) negative for hepatitis B (HBsAg) and hepatitis C, 3) fatty liver based on US and CT, 4) no other liver disease.

Individuals having the following criterion were defined as having DM: fasting plasma glucose > 7.0 mmol/L.

Statistical analysis

Statistical analyses were performed using SAS software (version 9.0).

Clinical and biochemical characteristics were compared between men and women using the Wilcoxon Scores test or Chi-Square test.

The sex-specific prevalence of abnormal metabolic conditions, and metabolic syndrome were correlated to levels of AST and ALT.

Independent associations between serum aminotransferase levels and metabolic syndrome, hyperlipidemia, NAFLD and DM were investigated using logistic regression models. The independent variables used were age, BMI, smoking, alcohol intake, waist circumference, occupation (peasant/ laborer, small private businessman, cadre officials), cultural and educational level (>8 years of study, or ≤8 years of study), income level (>800 RMB or ≤800 RMB every month). Drinkers were classified as regular alcohol drinkers (individuals whose alcohol consumption more than 40 g per week for more than 4 consecutive years), infrequent drinkers, and non-drinkers. Smokers were defined as individuals who smoked 10 or more cigarettes a day for more than 4 consecutive years. The thresholds for aminotransferase values were generated by ROC analysis. A two-sided $P < 0.05$ was considered statistically significant.

Results

The clinical characteristics and laboratory data of the 1761 men and 2074 women are shown in Table 1. Compared with women, men had higher ALT, AST levels and metabolic risk factors except HDL-cholesterol levels and there was no difference in LDL-cholesterol levels. Smoking and drinking were significantly more common in men than in women.

Serum AST levels were positively associated with all five metabolic abnormalities except glucose in both sexes. On the contrary, serum ALT levels were positively associated with all five metabolic abnormalities in both sexes except HDL-cholesterol in women (Table 2).

Univariate analysis for the prevalence of metabolic syndrome increased progressively according to the elevated serum ALT levels. The association between the elevated ALT levels, and the prevalence of metabolic syndrome was attenuated, but was still highly significant in both genders in multivariate analysis. However,

elevated AST level was attenuated significantly in both genders ($P > 0.05$) except for in the 40-49 IU/ml levels in women (Table 3).

In a further analysis, we compared the relative significance of individual liver enzymes by including AST and ALT in the same model. In this model, the prevalence of metabolic syndrome was significantly associated only with the elevated ALT levels ($P < 0.001$ for both sexes), but not with elevated AST levels (Table 3).

By multivariate analysis, the odds ratios for the prevalence of hyperlipidemia increased progressively according to the increases of serum aminotransferase levels except for ALT in women. Multivariate analysis odds ratios for the prevalence of DM increased progressively according to the increases in serum ALT levels. Univariate analysis odds ratios for the prevalence of NAFLD increased progressively according to increases in serum aminotransferase levels except AST in women (data not shown). The association between ALT level and the prevalence of NAFLD was attenuated, but still highly significant in multivariate analysis (Table 4).

A positive association between elevated ALT levels and the prevalence of MS, hyperlipemia, DM and NAFLD was observed even within the normal range of aminotransferase levels (Table 2, 4). The associations between AST and the prevalence of hyperlipidemia, DM and, NAFLD are not shown because the associations in the results were weaker, especially after multivariate adjustment.

We assessed the association between elevated ALT and AST levels, and the prevalence of metabolic syndrome in non-drinkers and drinkers, separately. The positive association between serum ALT and AST levels, and the prevalence of metabolic syndrome were not affected by alcohol intake. The most positive association between serum AST levels, and the prevalence of metabolic syndrome was found for levels of 40-49 IU compared with <20 IU in the non-drinker group, but not in the drinker group (Table 5).

Table 6 shows the thresholds for ALT values from ROC analyses of various diseases ($P < 0.05$). The P values for thresholds of AST for various

diseases were more than 0.05. AST values are not shown.

Table 1: Clinical and biochemical characteristics of study participants

| Characteristics | Men (n=1761) | Women (n=2074) | P value |
|--------------------------------------|----------------------|----------------------|---------|
| Median (Minimum-maximum) | | | |
| Age (yrs) | 46.00(18.00-75.00) | 46.00(18.00-79.00) | >0.05 |
| Body mass index (kg/m ²) | 24.11(12.88-54.36) | 23.52(12.11-61.68) | <0.01 |
| Waist circumference (cm) | 84.00(26.00-117.00) | 79.00(27.00-118.00) | <0.01 |
| Systolic blood pressure (mmHg) | 130.00(80.00-230.00) | 120.00(80.00-240.00) | <0.01 |
| Diastolic blood pressure (mmHg) | 82.00(40.00-125.00) | 80.00(40.00-120.00) | <0.01 |
| Glucose (mmol/L) | 5.04(3.26-20.60) | 4.76(3.20-17.10) | <0.01 |
| Total cholesterol (mmol/L) | 4.36(0.22-10.60) | 4.24(0.63-10.71) | <0.01 |
| LDL-cholesterol (mmol/L) | 3.00(0.10-12.40) | 2.97(0.10-9.70) | >0.05 |
| HDL-cholesterol, (mmol/L) | 1.30(0.11-5.82) | 1.40(0.00-8.00) | <0.01 |
| Triglyceride (mmol/L) | 1.30(0.20-22.99) | 1.19(0.19-31.89) | <0.01 |
| ALT (IU/L) | 21.20(1.00-211.70) | 15.00(0.60-645.90) | <0.01 |
| AST (IU/L) | 22.00(1.00-188.90) | 19.50(1.00-449.90) | <0.01 |
| Non-smoker, n (%) | 752(42.70) | 1629(78.54) | <0.01 |
| Smoker, n (%) | 1009(57.30) | 445(21.46) | |
| Non-drinker, n (%) | 523(29.70) | 1934(93.25) | <0.01 |
| Infrequent drinker, n (%) | 63(3.58) | 3(0.14) | |
| Regular alcohol drinker, n (%) | 1175(66.72) | 137(6.61) | |

Wilcoxon test scores for the continuous variables, Cochran-Mantel-Haenszel test for the categorical variables /ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high density lipoprotein; LDL, low density lipoprotein

Table 2: Prevalence (%) of metabolic abnormalities associated with serum aminotransferase levels

| Metabolic Abnormalities | Alanine aminotransferase, IU/L | | | | | P for trend | Aspartate aminotransferase, IU/L | | | | | P for trend |
|-------------------------------|--------------------------------|-------|-------|-------|-------|-------------|----------------------------------|-------|-------|-------|-------|-------------|
| | <20 | 20-29 | 30-39 | 40-49 | ≥50 | | <20 | 20-29 | 30-39 | 40-49 | ≥50 | |
| Men | | | | | | | | | | | | |
| Hypertension-positive | 37.32 | 45.70 | 54.62 | 53.70 | 57.33 | 0.01 | 39.50 | 45.54 | 50.25 | 50.79 | 63.64 | 0.01 |
| Central obesity | 18.60 | 34.00 | 44.96 | 54.63 | 63.33 | 0.01 | 27.12 | 31.87 | 38.58 | 44.44 | 63.64 | 0.01 |
| Triglyceride ≥1.7 (mmol/L) | 20.44 | 35.54 | 49.58 | 56.48 | 64.67 | 0.01 | 25.39 | 33.82 | 47.72 | 61.90 | 70.45 | 0.01 |
| HDL-cholesterol <1.3 mmol/L | 53.57 | 57.84 | 54.62 | 62.96 | 64.67 | 0.01 | 58.62 | 56.04 | 51.78 | 50.79 | 56.82 | 0.11 |
| Glucose >5.6 (mmol/L) | 19.95 | 23.40 | 26.47 | 32.41 | 32.00 | 0.01 | 23.82 | 22.71 | 22.34 | 25.40 | 36.36 | 0.35 |
| Women | | | | | | | | | | | | |
| Hypertension-positive | 31.64 | 43.97 | 43.54 | 51.52 | 56.72 | 0.01 | 31.49 | 38.26 | 47.96 | 63.27 | 51.52 | 0.01 |
| Central obesity | 34.25 | 50.94 | 68.52 | 74.24 | 67.16 | 0.01 | 36.39 | 43.43 | 52.04 | 83.67 | 63.64 | 0.01 |
| Triglyceride ≥1.7 (mmol/L) | 22.19 | 33.78 | 43.52 | 46.97 | 55.22 | 0.01 | 23.32 | 28.91 | 33.67 | 65.31 | 42.42 | 0.01 |
| HDL-cholesterol <1.3 (mmol/L) | 46.23 | 42.90 | 44.44 | 48.48 | 53.73 | 0.57 | 49.55 | 41.29 | 37.76 | 48.98 | 51.52 | 0.03 |
| Glucose >5.6 (mmol/L) | 11.99 | 17.16 | 13.89 | 18.18 | 14.93 | 0.04 | 13.07 | 12.63 | 16.33 | 20.41 | 18.18 | 0.16 |

HDL, high density lipoprotein;

Table 3: Independent Associations between serum aminotransferase levels and the metabolic syndrome

| Aminotransferase levels | Number | Odds Ratio (95% CI) for Metabolic Syndrome | | | |
|-------------------------|--------|--|-------------------|------------------------|------------------------|
| | | Metabolic Syndrome n (%) | Univariate | Multivariate Adjusted* | Multivariate adjusted† |
| Men | | | | | |
| ALT<20 (I U/L) | 812 | 84(10.34) | 1 | 1 | 1 |
| 20-29 | 453 | 115(25.39) | 2.95(2.16-4.02) | 1.79(1.15-2.80) | 1.92(1.20-3.06) |
| 30-39 | 238 | 77(32.35) | 4.14(2.91-5.90) | 1.80(1.17-3.04) | 2.50(1.14-3.53) |
| 40-49 | 108 | 47(43.52) | 6.68(4.29-10.39) | 1.81(1.21-3.59) | 2.97(1.27-4.01) |
| >50 | 150 | 80(53.33) | 9.90(6.69-14.66) | 3.31(1.87-5.87) | 3.52(1.96-6.32) |
| Total | 1761 | 403(22.88) | | | |
| AST<20 (IU/L) | 638 | 112(17.55) | 1 | 1 | 1 |
| 20-29 | 819 | 189(23.08) | 1.41(1.09-1.83) | 1.13(0.77-1.65) | 0.99(0.66-1.49) |
| 30-39 | 197 | 56(28.43) | 1.87(1.29-2.70) | 1.20(0.68-2.13) | 1.13(0.64-2.00) |
| 40-49 | 63 | 23(36.51) | 2.70(1.56-4.69) | 1.78(0.76-4.17) | 1.75(0.75-4.08) |
| >50 | 44 | 23(52.27) | 5.14(2.75-9.62) | 2.32(0.93-5.76) | 2.33(0.95-5.76) |
| Total | 1761 | 403(22.88) | | | |
| Women | | | | | |
| ALT<20 (IU/L) | 1460 | 225(15.41) | 1 | 1 | 1 |
| 20-29 | 373 | 108(28.95) | 2.24(1.72-2.92) | 1.40(1.25-1.95) | 1.38(1.27-1.95) |
| 30-39 | 108 | 43(39.81) | 3.63(2.41-5.48) | 1.46(1.19-2.35) | 1.54(1.26-2.35) |
| 40-49 | 66 | 36(54.55) | 6.59(3.98-10.91) | 3.09(1.62-5.89) | 3.06(1.60-5.86) |
| >50 | 67 | 33(49.25) | 5.33(3.23-8.78) | 2.63(1.36-5.11) | 2.62(1.35-5.09) |
| Total | 2074 | 445(21.46) | | | |
| AST<20 (IU/L) | 1102 | 188(17.06) | 1 | 1 | 1 |
| 20-29 | 792 | 180(22.73) | 1.43(1.14-1.80) | 1.18(0.89-1.58) | 1.08(0.80-1.47) |
| 30-39 | 98 | 28(28.57) | 1.95(1.22-3.10) | 1.15(0.64-2.07) | 0.99(0.54-1.82) |
| 40-49 | 49 | 34(69.99) | 11.02(5.88-20.64) | 6.19(2.82-13.56) | 5.65(2.57-2.42) |
| >50 | 33 | 15(45.45) | 4.05(2.01-8.18) | 2.11(1.80-5.62) | 2.01(1.76-5.34) |
| Total | 2074 | 445(21.46) | | | |

* Adjusted for age, BMI, occupation, cultural and educational level, income level, smoking, alcohol intake, and waist circumference

† Adjusted for age, BMI, occupation, cultural and educational level, income level; smoking, alcohol intake, waist circumference, and (ALT or AST).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index

Table 4: Independent Associations between serum aminotransferase levels and hyperlipidemia, DM and, NAFLD

| Aminotransferase Level | Number | Odds Ratio (95% CI) for DM | | Odds Ratio (95% CI) for NAFLD | | Odds Ratio (95% CI) for Hyperlipemia | |
|------------------------|--------|----------------------------|------------------------|-------------------------------|------------------------|--------------------------------------|------------------------|
| | | DM n (%) | Multivariate Adjusted* | NAFLD n (%) | Multivariate Adjusted* | Hyperlipemia, n(%) | Multivariate Adjusted* |
| Men | | | | | | | |
| ALT<20 (IU/L) | 812 | 29(3.57) | 1 | 50(6.16) | 1 | 259(31.90) | 1 |
| 20-29 | 453 | 32(7.06) | 1.69(0.99-2.89) | 54(11.92) | 1.35(0.87-2.09) | 209(46.14) | 1.35(1.15-1.74) |
| 30-39 | 238 | 16(6.72) | 1.44(0.75-2.79) | 34(14.29) | 1.50(1.29-2.51) | 137(57.56) | 1.92(1.39-2.64) |
| 40-49 | 108 | 8(7.41) | 1.41(0.60-3.31) | 34(31.48) | 3.26(1.84-5.77) | 72(66.67) | 2.53(1.59-4.02) |
| >50 | 150 | 17(11.33) | 2.29(1.16-4.54) | 51(34.00) | 3.66(2.19-6.11) | 113(75.33) | 3.44(2.24-5.29) |
| Total | 1761 | 102(5.79) | | 223(12.66) | | 790(44.86) | |
| Women | | | | | | | |
| ALT<20 (IU/L) | 1460 | 51(3.49) | 1 | 194(13.29) | 1 | 655(44.86) | 1 |
| 20-29 | 373 | 20(5.36) | 1.36(1.19-2.34) | 100(26.81) | 1.58(1.13-2.21) | 210(56.30) | 1.24(0.97-1.59) |
| 30-39 | 108 | 5(4.63) | 1.28(1.16-2.85) | 45(41.67) | 1.89(1.11-3.20) | 62(57.41) | 0.94(0.61-1.45) |
| 40-49 | 66 | 10(15.15) | 3.86(1.81-8.26) | 31(46.97) | 2.44(1.30-4.58) | 44(66.67) | 1.37(0.79-2.39) |
| >50 | 67 | 8(11.94) | 2.72(1.17-6.33) | 32(47.76) | 3.23(1.70-6.14) | 46(68.66) | 1.70(0.97-2.99) |
| Total | 2074 | 94(4.53) | | 402(19.38) | | 1017(49.04) | |

* Adjusted for age, BMI, occupation, cultural and educational level, income level, smoking, alcohol intake, and waist circumference. ALT, alanine aminotransferase; AST, aspartate aminotransferase; DM, diabetes mellitus; NAFLD, non-alcoholic fatty liver disease; BMI, body mass index. The Odds Ratio between AST and metabolic disorders was not shown because the associations in the results were weaker, especially after multivariate adjustment

Table 5: Association between serum aminotransferase levels and metabolic syndrome by alcohol drinking status

| Risk factor | Drinker | | | Non-drinker | | |
|--------------------------|---------|-------------------------|---------------------|-------------|-------------------------|---------------------|
| | Number | Metabolic syndrome n(%) | Odds Ratio (95% CI) | Number | Metabolic syndrome n(%) | Odds Ratio (95% CI) |
| alanine aminotransferase | | | | | | |
| ALT<20 IU/L) | 652 | 75(11.50) | 1 | 1620 | 234(14.44) | 1 |
| 20-29 | 348 | 90(25.86) | 2.02(1.24-3.29) | 103 | 133(27.82) | 1.40(1.02-1.91) |
| 30-39 | 189 | 64(33.86) | 1.95(1.11-3.43) | 99 | 56(35.67) | 1.44(1.28-2.33) |

Table 5: Continued...

| | | | | | | |
|-----------------------------|-----|------------|-----------------|------|------------|------------------|
| 40-49 | 75 | 35(46.67) | 2.81(1.30-6.07) | 157 | 48(48.48) | 2.31(1.32-4.05) |
| >50 | 114 | 59(51.75) | 3.49(1.89-6.43) | 478 | 54(52.43) | 3.02(1.71-5.34) |
| Aspartate amino-transferase | | | | | | |
| AST<20(IU/L) | 507 | 92(18.15) | 1 | 1233 | 208(16.87) | 1 |
| 20-29 | 613 | 137(22.35) | 1.11(0.73-1.70) | 998 | 232(23.25) | 1.20(0.91-1.57) |
| 30-39 | 165 | 51(30.91) | 1.40(0.77-2.53) | 130 | 33(25.38) | 1.02(0.58-1.79) |
| 40-49 | 53 | 21(39.62) | 1.88(1.62-4.31) | 59 | 36(61.02) | 5.64(2.66-11.95) |
| >50 | 40 | 22(55.00) | 3.78(1.45-9.87) | 37 | 16(43.24) | 1.28(1.10-3.23) |

Odds ratios with 95% confidence intervals are adjusted for age, body mass index, occupation, cultural and educational level, income level, waist circumference, smoking status, and sex; ALT, alanine aminotransferase. AST, aspartate aminotransferase

Table 6: Thresholds for ALT values from ROC analyses

| | Threshold value (IU/L) | |
|-----------------------------------|------------------------|-------|
| | Men | Women |
| Diabetes mellitus | 23.45 | 21.90 |
| Hyperlipemia | 21.50 | 14.90 |
| Metabolic syndrome | 25.30 | 16.85 |
| Non-alcoholic fatty liver disease | 23.80 | 16.85 |

The people who had Diabetes mellitus or Hyperlipemia or Metabolic syndrome or Non-alcoholic fatty liver disease were defined as disease group and the others were control group in each ROC analyses

Discussion

We found a positive association between serum aminotransferase levels and metabolic disorders in the Chinese population. Recent epidemiologic studies have also reported an association between aminotransferase elevations and metabolic disorders such as metabolic syndrome, hyperlipemia, and DM (19). This association has been observed in various populations, including obese people, postmenopausal women, elderly men, patients with NAFLD, and even adolescents (2, 16, 20). Similar findings have already been reported in other countries such as Korea, Singapore and Japan (21). Another more important finding of this study is that the association was observed even in normal to near-normal aminotransferase levels, in a level-related manner. Aminotransferase levels of 40-49 IU/ml were very significantly related in women, and need further investigation. The reason for the

stronger association of ALT 40-49 IU/ml with the prevalence of metabolic syndrome compared to ALT over 50 is not clear, but may be related to the fact that the progression of liver damage in NAFLD is generally slow, and the levels of ALT are most commonly only mildly elevated. Similar findings also were reported in some Korean populations (22). We found that the association of ALT with the prevalence of metabolic syndrome persisted even after adjustment for waist circumference. This is in a way over-adjustment, because waist circumference is part of the definition of the metabolic syndrome, but provides additional insight by indicating that it is not simply the well-known association of obesity or abdominal obesity that mediates the association. NAFLD has been associated with metabolic disorders, including central obesity, dyslipidemia,

hypertension, and hyperglycemia, the major risk factors for the development of NAFLD (23). Because the number of metabolic syndrome components has increased, the prevalence and odds ratio for having increased ALT activity were also significantly increased (24). In the present study, metabolic disorder components (triglycerides, LDL, CHOL, etc.) and NAFLD were correlated with increased ALT activity. Unexplained elevations in ALT levels have been suggested to signify the presence of NAFLD in adults. Individuals with the metabolic disorders (MS, hyperlipemia and DM) have a significantly higher prevalence of unexplained elevations in ALT levels (24). Therefore, this also supports the notion that NAFLD is part of the spectrum of metabolic disorders.

The prevalence of NAFLD is mainly associated with the male sex, obesity and waist circumference, but it may vary significantly among different population groups (22). Recent studies have added evidence that insulin resistance, a key component of the MS and DM may contribute to the development of NAFLD (24). Central obesity may be an underlying cause of insulin resistance, and can also contribute to the development of NAFLD (2). Compared with adipose tissue in other sites, visceral adipose tissue is more resistant to insulin, and the associated relative hyperinsulinemia promotes lipogenesis in the liver, which contributes to NAFLD (25).

Asians have been shown to have more subcutaneous fat, and have a different fat distribution compared to Caucasians. The relationship between body mass index (BMI) and body fat percentages in different population groups have been shown to vary (23-24). Thus, the significance of central obesity in connection with liver dysfunction and metabolic disorders may differ by ethnicity. The connection in the present study was similar to that found in another previous study (22).

Some conditions such as alcohol consumption, viral hepatitis or hemochromatosis, which can increase aminotransferase activity, may also be

associated with the metabolic syndrome. The association between metabolic risk factors and ALT elevation was shown to be similar in subjects with and without identifiable causes of chronic liver disease, (alcohol use) (26). The association was also seen in the non-drinker or drinker regression model in the present study. Some systemic diseases and medications may also elevate serum aminotransferase levels. Accordingly, we performed further analysis after excluding 524 people who were receiving hormone replacement therapy or medications for hypertension, diabetes mellitus, liver disease, renal disease during three months before examination. We still found a strong association between serum aminotransferase levels and MS, even in the groups with normal to near-normal range of aminotransferases. For MS patients with levels below 20 IU/L, the adjusted odds ratios for ALT levels of 20-29, 30-39, 40-49 and > 50 IU/L were 1.82, 2.08, 1.88 and 2.72 in men and 1.37, 1.34, 3.07 and 2.46 in women, respectively ($P < 0.05$ for all). In addition, patients with hyperlipemia and DM had the same trend.

In the present study, serum ALT levels were more closely associated with MS than AST levels. In addition, only ALT levels were significantly associated with MS when both enzymes were simultaneously investigated in a single model. This finding is in agreement with previous studies, and can be explained by a higher specificity of ALT for liver disease (22). The cutoff level of aminotransferase that discriminates between healthy and diseased livers has not been clearly defined. Several previous studies have demonstrated that serum aminotransferase levels, even within the normal range, may be associated with morbidity and mortality (27). In liver disease, elevated serum aminotransferase levels have a more positive association with non-alcoholic steatohepatitis than other frequent causes of hepatitis (alcoholic hepatitis, chronic hepatitis B and C) and some rare causes (autoimmune hepatitis) (26).

From the multivariate analysis of patients with metabolic disorders, the linear association between serum aminotransferase levels (especially ALT at 20-29 IU/L levels compared to the lowest levels (<20 IU/L)) suggests that people with high normal aminotransferase levels may need further investigation for the presence of metabolic disorders such as MS. Considering the increasing prevalence of metabolic disorders and their association with liver dysfunction, the significance of the serum aminotransferase assay needs to be re-evaluated. Therefore, we evaluated thresholds for aminotransferase values by ROC analysis. Serum ALT levels of 21-25 IU/L for men, and 17-22 IU/L for women are suggested as cutoff levels that detect metabolic disorders affecting the liver.

In a recent study from Korea, calculated thresholds for ALT values were 35 IU/L for men and 26 IU/L for women (28). Relatively high threshold levels of normal serum aminotransferase were also found in our study. Therefore, adjustment of the normal limit of serum aminotransferases should be considered for monitoring liver function, especially in people with metabolic disorders.

One of the limitations in the present study is that the diagnosis of a fatty liver was based on ultrasound imaging and CT, and not confirmed by liver biopsy, the gold standard for the assessment of liver histology and a key test to diagnose NAFLD.

Ethical considerations

Ethical issues (Including plagiarism, Informed Consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc) have been completely observed by the authors.

Acknowledgments

This work was supported by the grants from the National Natural Science Foundation (NO.

30972611, NO.30872174 and NO. 81172726) and the National S T Major Project of China (NO. 2008ZX10002-004). The authors declare that there is no conflict of interests.

Abbreviations

ALT, alanine aminotransferase; BMI, body mass index; CHOL, Total cholesterol; FPG, fasting plasma glucose; HBV, hepatitis B virus; HCV, hepatitis C virus; HDL, high density lipoprotein; LDL, low density lipoprotein; MS, Metabolic Syndrome; NAFLD, non-alcoholic fatty liver disease.

References

1. Luyckx FH, Lefebvre PJ, Scheen AJ (2000). Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. *Diabetes Metab*, 26: 98-106.
2. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology*, 37: 917-23.
3. Xanthakos S, Miles L, Bucuvalas J, Daniels S, Garcia V, Inge T (2006). Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. *Clin Gastroenterol Hepatol*, 4: 226-32.
4. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al. (2007). Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. *J Gastroenterol Hepatol*, 22: 1482-9.
5. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP (2007). Nonalcoholic fatty liver disease in severely obese subjects. *Am J Gastroenterol*, 102: 399-408.
6. Choi SY, Kang JH, Park MJ, Lee HS (2008). Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis. *Korean J Hepatol*, 14: 77-88.

7. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. (2008). Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. *Hepatology*, 48: 792-8.
8. Zhu LY HL, Li XL, Wang GY, Shan W, Ma LC, Wang XH (2010). Relationship between Trp64Arg mutation in the β 3-adrenergic receptor gene and metabolic syndrome: a seven-year follow-up study. *Chin Med J (Engl)*, 123: 2375-8.
9. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. (1999). Liver pathology and the metabolic syndrome X in severe obesity. *J Clin Endocrinol Metab*, 84: 1513-7.
10. Pagano G PG, Musso G, Gambino R, Mecca F, Depetris N (2002). Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. *Hepatology*, 35: 367-72.
11. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, et al. (2003). Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. *J Gastroenterol Hepatol*, 18: 588-94.
12. Tian JL, Zhang Y, Chen BY (2010). Sleep apnea hypopnea syndrome and liver injury. *Chin Med J (Engl)*, 123: 89-94.
13. Kelishadi R CS, Amra B, Adibi A (2009). Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. *Atherosclerosis*, 204: 538-43.
14. Oh SY CY, Kang MS, Yoo TW, Park JH (2006). The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. *Metabolism*, 55:1604-9.
15. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I (2004). Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. *BMJ*, 328: 983.
16. Liu M, Yan HM, Gao X, Gao J (2007). [Association of abnormality of liver enzymes and metabolic syndrome in patients with nonalcoholic fatty liver disease]. *Zhonghua Yi Xue Za Zhi*, 87: 253-5.
17. Sanyal AJ (2002). AGA technical review on nonalcoholic fatty liver disease. *Gastroenterology*, 123: 1705-25.
18. Alberti KG, Zimmet P, Shaw J (2006). Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med*, 23: 469-80.
19. Liangpunsakul S, Chalasani N (2005). Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). *Am J Med Sci*, 329: 111-6.
20. Finelli C CP, Contaldo F, Pasanisi F (2005). Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. *Ann Nutr Metab*, 49: 289-95.
21. Saito T, Nishise Y, Makino N, Haga H, Ishii R, Okumoto K, et al. (2009). Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population. *Metabolism*, 58: 1067-75.
22. Kim HC, Choi KS, Jang YH, Shin HW, Kim DJ (2006). Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. *Yonsei Med J*, 47: 542-50.
23. Nah EH, Park JY (2008). Metabolic characteristics and associated factors of non-alcoholic fatty liver disease diagnosed at medical checkups. *Korean J Lab Med*, 28: 244-50.
24. Omagari K KY, Masuda J, Egawa I, Sawa T, Hazama H (2002). Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. *J Gastroenterol Hepatol*, 17: 1098-105.
25. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, et al. (2002). Removal of visceral fat prevents insulin resistance and glucose intolerance of

- aging: an adipokine-mediated process? *Diabetes*, 51: 2951-8.
26. Deurenberg P D-YM, Guricci S (2002). Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. *Obes Rev*, 3: 141-6.
27. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G (1999). The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. *Scand J Gastroenterol*, 34: 85-91.
28. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, et al. (2010). Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. *Hepatology*, 51: 1577-83.

Archive of SID